PMID- 29254297
OWN - NLM
STAT- MEDLINE
DCOM- 20180222
LR  - 20180222
IS  - 0393-974X (Print)
IS  - 0393-974X (Linking)
VI  - 31
IP  - 4
DP  - 2017 Oct-Dec
TI  - Propolis nasal spray effectively improves recovery from infectious acute rhinitis 
      and common cold symptoms in children: a pilot study.
PG  - 943-950
AB  - Currently, treatment for acute rhinitis (AR) is symptomatic but no clear 
      agreement exists to control its development. Propolis extract may appear as a 
      promising natural treatment for AR, but its beneficial effects have not yet been 
      fully tested. Forty children suffering from AR and common cold symptoms aged 
      between 2-12 years were enrolled in a prospective epidemiological multicentre 
      study. A 7-day treatment with propolis nasal spray (3 times/day) was applied and 
      a comparison of symptomatology, subjective global improvement and quality of life 
      (QoL) between baseline (day 1) and final (day 7) visits were performed. The main 
      goal was to evaluate the changes in symptom intensity using the Jackson’s scoring 
      test. After 7 days of treatment there was a significant decrease of symptoms both 
      in the total score (p less than 0.0001) and in regard to each AR symptom (p less 
      than 0.01). On the whole, the sample reported no symptoms by day 7, and the 
      resolution of symptoms occurred approximately at day 4. Furthermore, there was no 
      need for supplementary treatment. Both the subjective global improvement 
      impression and the QoL of patients appeared to significantly improve after 
      treatment. No adverse events (AEs) were found globally. It can be concluded that 
      propolis nasal spray effectively improves recovery from infectious AR and common 
      cold symptoms in children and is an optimal alternative in the treatment of this 
      disease without need for any adjuvant treatment.
FAU - Marti, J
AU  - Marti J
AD  - Pediatric Service Primary Care, La Marina Primary Care Center, Barcelona, Spain.
FAU - Lopez, F
AU  - Lopez F
AD  - Pediatric Service Primary Care, El Clot Primary Care Center, Barcelona, Spain.
FAU - Gascon, I
AU  - Gascon I
AD  - Pediatric Service Primary Care, La Marina Primary Care Center, Barcelona, Spain.
FAU - Julve, J
AU  - Julve J
AD  - Pharmalink, S.L., Parc Tecnologic del Valles, Cerdanyola, Spain.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - Italy
TA  - J Biol Regul Homeost Agents
JT  - Journal of biological regulators and homeostatic agents
JID - 8809253
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Nasal Sprays)
RN  - 9009-62-5 (Propolis)
SB  - IM
MH  - Acute Disease
MH  - Administration, Intranasal
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Common Cold/diagnosis/*drug therapy/physiopathology
MH  - Female
MH  - Humans
MH  - Male
MH  - *Nasal Sprays
MH  - Pilot Projects
MH  - Propolis/*therapeutic use
MH  - Prospective Studies
MH  - Quality of Life/psychology
MH  - Rhinitis/diagnosis/*drug therapy/physiopathology
MH  - Treatment Outcome
EDAT- 2017/12/20 06:00
MHDA- 2018/02/23 06:00
CRDT- 2017/12/20 06:00
PHST- 2017/12/20 06:00 [entrez]
PHST- 2017/12/20 06:00 [pubmed]
PHST- 2018/02/23 06:00 [medline]
AID - 12 [pii]
PST - ppublish
SO  - J Biol Regul Homeost Agents. 2017 Oct-Dec;31(4):943-950.